QN
Quince Therapeutics, Inc.
QNCX · NASDAQ
$26.50 -7.26% (-$2.07)
1M -17.44%
Market Cap $7.38M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$34.48
30.1% upside
Current Price
$26.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, QNCX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
-
N/A P/E N/A
EV/EBITDA N/A
P/S N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 104.64%
ROA 74.58%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 14.52x
Debt/Equity N/A
Int. coverage N/A
Stability
33 /100
Unstable Beta 1.31x
EPS volatility 52.41%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about QNCX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dirk Thye
Employees
38
Headquarters
South San Francisco
Upcoming events
11 NOV
Earnings
Upcoming earnings report